Bank Of New York Mellon Corp Verve Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$17.85 - $40.7 $3.11 Million - $7.1 Million	174,392 New	174,392 $3.37 Million
Q3 2022 Nov 14, 2022	BUY	$15.63 - $41.49 $1.04 Million - $2.75 Million	66,322 Added 64.04%	169,878 $5.84 Million
Q2 2022 Aug 15, 2022	SELL	$11.14 - $23.17 $136,253 - $283,392	-12,231 Reduced 10.56%	103,556 $1.58 Million
Q1 2022 May 11, 2022	BUY	$20.92 - $39.36 $766,759 - $1.44 Million	36,652 Added 46.32%	115,787 $2.64 Million
Q4 2021 Feb 11, 2022	BUY	$31.94 - $54.82 $730,691 - $1.25 Million	22,877 Added 40.66%	79,135 $2.92 Million
Q3 2021 Nov 12, 2021	BUY	$46.0 - $73.99 $2.59 Million - $4.16 Million	56,258 New	56,258 $2.64 Million

186

73.3M

85K

215K

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $317M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.